Compare KAI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KAI | LGND |
|---|---|---|
| Founded | 1991 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | KAI | LGND |
|---|---|---|
| Price | $289.69 | $189.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $340.00 | $144.71 |
| AVG Volume (30 Days) | ★ 143.8K | 139.7K |
| Earning Date | 10-28-2025 | 08-05-2025 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,024,074,000.00 | $181,488,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $10.56 | $18.87 |
| P/E Ratio | $33.78 | ★ N/A |
| Revenue Growth | N/A | ★ 53.40 |
| 52 Week Low | $244.87 | $81.74 |
| 52 Week High | $409.73 | $129.90 |
| Indicator | KAI | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 45.58 |
| Support Level | $276.80 | $179.65 |
| Resistance Level | $300.44 | $192.44 |
| Average True Range (ATR) | 9.69 | 6.57 |
| MACD | 2.66 | -2.06 |
| Stochastic Oscillator | 72.75 | 31.70 |
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.